For a second consecutive year Therapure Biopharma Inc. ranks in the top 100 of the PROFIT 500 list of the Fastest-Growing Companies in Canada, and ranks 18th on the list of Canada’s Fastest-Growing Manufacturing Companies

  • Posted on: 29 September 2015
  • By: admin001

Mississauga, Ontario (Sept 21, 2015) – Therapure Biopharma Inc. is pleased to announce that it placed 89th in the 27th annual PROFIT 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and PROFIT. Published in the October issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 profiles the country’s most successful growth companies and ranks them by their five-year revenue growth. Therapure is especially pleased to announce that it ranked 18th on the list of Canada’s Fastest-Growing Manufacturing Companies in 2015.

“The PROFIT 500 represent the highest tier of entrepreneurialism in Canada,” says James Cowan, Editor-in-chief of PROFIT and Canadian Business. “They should be lauded for the positive economic contributions they’ve made to their communities—and the entire country. They are examples of what can be accomplished with innovation, discipline and determination.”

“Therapure is honoured to be in the PROFIT 500 ranking for a second consecutive year, says Nick Green, Therapure’s President and CEO. “We are extremely fortunate to work in an industry that attracts dedicated and passionate people, and one where we are motivated by the positive impact we can have on people’s lives. Each Therapure employee brings an attention to detail and a personal commitment to quality to everything they do, and it is this dedication to seeing all projects through to a successful outcome that makes me most proud. In the end, it is this attitude that has enabled us to achieve our growth.”

Since 2010, Therapure has achieved a compound annual growth rate in revenues of approximately 57% through its Therapure Biomanufacturing division by focusing on the production of complex biological drugs for a broad range of Canadian and international customers.

Therapure Biomanufacturing’s capabilities and expertise include cell line development, upstream and downstream process development, cGMP manufacturing for preclinical, clinical and commercial drug supply and aseptic fill/finish of injectable drugs. These integrated services allowTherapure to compete successfully in the global biomanufacturing sector.

COMPANY CONTACT:

Dina Iezzi
Director, Marketing and Special Projects
diezzi@therapurebio.com
(905) 286-6270